Short answer
Septerna, Inc. (SEPN) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $27M (up 22375.6% year over year) with net income of −$13M.
Q2 2026 key financials · XBRL
- Revenue
- $27M
- +22375.6% YoY · +0.8% QoQ
- Net income
- −$13M
- +47.5% YoY · −50.9% QoQ
- Operating margin
- -62.9%
- EPS (diluted)
- −$0.29
- +48.2% YoY · −52.6% QoQ
Source: XBRL data from the Septerna, Inc. (SEPN) Q2 2026 10-Q on SEC EDGAR. USD.
Septerna, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added or changed risk factor identified; filing retains the 2025 Form 10-K risk framework
- Regulatory risk: extensive product-candidate regulation may delay or prevent required marketing approvals
- Clinical-development risk: no advanced clinical trials completed, leaving commercialization years away or uncertain
- Operational risk: dependence on third-party manufacturers, CROs, and CMOs for compliant supply and testing
- Liquidity risk: $516.5 million in cash, cash equivalents, and marketable securities expected to fund operations at least twelve months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Septerna, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.